Benitec Biopharma Limited is an Australian biotechnology company founded in 1997.[1] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.[2]
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.[3]
Research and development
Benitec Biopharma is researching ddRNAi in the following fields:
External links
References
- Benitec Biopharma Australian Securities Exchange, retrieved 11 April 2012^
- GlobalData Financial and Strategic SWOT Analysis Review GlobalData, retrieved 11 April 2012^
- Licensing RNAi gene technology. CSIRO. 14 Oct 2011 CSIRO, retrieved 12 April 2012^
- Biomics Biotechnologies – Pipeline Biomics Biotechnologies, retrieved 21 January 2014^
- Bioshares Edition 434. 25 November 2011 Bioshares, retrieved 21 January 2014^
- Benitec Biopharma Annual Report 2011 Benitec, retrieved 16 January 2014^